Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche study shows Herceptin benefits

Roche study shows Herceptin benefits

12th March 2009

Roche has revealed that women with HER2 positive early breast cancer continue to benefit from Herceptin several years after they have finished treatment.

In collaboration with the Breast International Group, the company conducted a study called Hera and found that female patients who received the drug were 25 per cent less likely to suffer from the disease returning than those who did not receive it.

After four years, the study revealed almost 90 per cent of women who had undergone Herceptin treatment were still alive.

William M Burns, chief executive officer of Roche’s pharmaceuticals division, commented: “These important long-term results from the Hera trial reinforce that women with this aggressive type of cancer have the best chance of cure with Herceptin.”

The study is one of four large investigations of the drug to date, all of which have demonstrated that the treatment can prolong survival in women with HER2 positive early breast cancer.

In other news, Roche announced this week that it would raise dividends for shareholders by nine per cent.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.